DC2022 Speakers confirmed to date
Prof Ken Shortman - Patron of DC2022
Walter and Eliza Hall Institute (WEHI)
Ken Shortman obtained his PhD in 1964 at the Walter and Eliza Hall Institute (WEHI) with GL Ada and FM Burnet. After post-doctoral training at INSERM, Gif-sur Yvette, France and Stanford University, USA, he returned to WEHI in 1964. He has been at WEHI since then, with sabbatical visits to Switzerland at ISREC and the Ludwig Institute, Lausanne, the Basel institute of Immunology and the University of Zurich and to France at the Schering-Plough Institute. More recently he has been visiting Professor at the Institute Curie, France and at the Immunology Programme, National University of Singapore. In 2000 he organised, with Derek Hart, the International DC meeting in Port Douglas, Australia. He currently has an honorary position at WEHI. He has been successively a biochemist involved with nucleic acid metabolism, a biophysicist involved with cell separation technology, an immunlologist investigating T cell development in the thymus and finally, since about 1990, a DC enthusiast investigating DC subset function and development.
Prof Sebastian Amigorena
Institut Curie, France
Sebastian Amigorena obtained his PhD in Paris in 1990. After a 3 years post doc at Yale University, he returned to Paris in 1995 and started an Inserm AVENIR group together with Christian Bonnerot. Today, he is the head of the Immunology Department (INSERM U932, “Cancer Immunity”) at the Curie Institute. Sebastian Amigorena’s main scientific interest overlaps immunology and cell biology. In his graduate and post-doctoral studies, he analyzed the functions of IgG receptors and described the molecular basis of their inhibitory properties. Sebastian Amigorena is today an expert in antigen presentation and cross presentation in dendritic cells. He analyzed dendritic cells’ endocytic and phagocytic pathways and described several unique specializations of both pathways. Sebastian Amigorena and his team also made significant contributions to the analysis of cytotoxic T cells dynamics in vivo, during the initiation of immune responses in lymph nodes and during the invasion and rejection of solid tumors. More recently, he has contributed to understanding the epigenetic programing of T cell memory.
Prof Zwi Bernemann
University of Antwerp, Belgium
Zwi N. Berneman, MD PhD FRCP is Professor of Hematology and Head of the Laboratory of Experimental Hematology at the University of Antwerp, Antwerp, Belgium and Head of the Division of Hematology at the Antwerp University Hospital. His basic and clinical research is focused on vaccination with immunogenic dendritic cells in cancer (acute myeloid leukemia, glioblastoma, mesothelioma) and with tolerogenic dendritic cells in multiple sclerosis; and on retargeting T-lymphocytes against cancer with T-cell receptors directed against the tumor-associated Wilms’ tumor antigen WT1. His laboratory has pioneered mRNA electroporation as a clinically safe gene transfer methodology and has applied it to the fields of dendritic cells and T-lymphocytes. He has been conducting clinical trials with cultured dendritic cells since 2005. For this, he helped establish the Center for Cell Therapy and Regenerative Medicine (CCRG) of which he is the Medical Director, at the Antwerp University Hospital and for which he obtained a Good Manufacturing Practices (GMP) Certification and Production License from the (Belgian) Federal Agency for Medicines and Health Products. He is a Fellow of the Royal College of Physicians, London, UK. He is the author or co-author of more than 300 peer-reviewed publications and his ISI h-index is 50.
Prof Nina Bhardwaj
Tisch Cancer Institute, USA
Dr. Bhardwaj is an immunologist who has made seminal contributions to human dendritic cell biology, specifically with respect to their isolation, subset discovery, immunobiology, antigen presenting function, and use as vaccine adjuvants in humans. She is the Director of Immunotherapy at the Icahn School of Medicine at Mount Sinai (ISMMS) and holds the Ward Coleman Chair in Cancer Research. Dr. Bhardwaj brings expertise in human immunology and a variety of immune therapies, having developed Toll Like Receptor (TLR) agonist- and dendritic cell-based vaccines for the treatment of both cancer and infection in several Investigator-Initiated studies, and more recently supplication of neoantigen vaccines into the clinic. Dr. Bhardwaj is an elected member of the American Society of Clinical Investigation and the American Association of Physicians, a recipient of the Doris Duke Distinguished Scientist Award and was named one of the Scientific American Magazine’s Top 50 Researchers, receiving the Award for Medical Research in 2004. She received the Fred W. Alt Award for new discoveries in Immunology in 2015 from The Cancer Research Institute. Dr. Bhardwaj is a senior editor of the AACR Cancer Immunology Research journal, senior editor for Frontiers in Immunology and consulting editor for the Journal of Clinical Investigation. She has also served on NIH Study Sections and multiple advisory councils. Dr. Bhardwaj was formerly chair of the Cancer Immunology Steering Committee of the AACR. Dr. Bhardwaj has also successfully acquired multiple federal and foundation grants and has authored over 200 publications. Dr. Bhardwaj will serve as temporary chair of the AACR Nominating Committee.
Prof Julie Magarian Blander
Weill Cornell Medicine, USA
Julie Magarian Blander is a Gladys and Roland Harriman Professor of Immunology in Medicine at Weill Cornell Medicine (WCM) In New York City. Dr. Blander received her Ph.D. from the University of Pittsburgh studying tumor immunology under the mentorship of Dr. Olivera Finn. She conducted her postdoctoral training with Drs. Charles Janeway and Ruslan Medzhitov at Yale University pioneering the study of the impact of Toll like receptors on macrophage and dendritic cell function. Dr. Blander’s laboratory studies various aspects of innate immunity and inflammation and their application to human disease. The laboratory was established in 2006 with the appointment of Dr. Blander as Assistant Professor at the Icahn School of Medicine at Mount Sinai (ISMMS). Dr. Blander’s promotion to Associate Professor with tenure in 2011 at ISMMS was followed five years later by an appointment as full professor with tenure at WCM-Cornell University in 2016. Dr. Blander is a member of the Sandra and Edward Meyer Cancer Center at WCM. She is a member of the Executive Committee for the Cornell Center for Immunology at Cornell University, Associate co-director of NIH T32 grant to the Department of Medicine Division of Gastroenterology and Hepatology, Course Director for the Advanced Topics of Immunology at the WCM/Sloan Kettering Institute Graduate School for Medical Sciences, member of the WCM Promotion and Appointment Review Committee, member of the WCM Research Awards Committee, member of the Senior Research Awards Committee for the Crohn’s and Colitis Foundation, editorial board member of the Elsevier journal Current Research in Immunology, and Nominations Committee member for the American Association of Immunologists (AAI). Dr. Blander had also served as a member of the Program Committee for the AAI (2016-2019). Dr. Blander has received a 2018 Daedalus Award for Innovation from WCM. She was named Searle Scholar in 2007 and a Burroughs Wellcome Investigator in the Pathogenesis of Infectious Disease in 2011. She has received the 2009 G. Jeanette Thorbecke
Society of Leukocyte Biology award, an American Cancer Society Research Scholar Award, a Leukemia and Lymphoma Society Scholar Award, and the J. V. Satterfield Arthritis Investigator Award from the Arthritis Foundation. Dr. Blander is currently funded by grants from Sanofi and the National Institutes of Health NIAID and NIDDK.
Prof Marco Colonna
Washington University School of Medicine in St.Louis, Missouri
Dr. Marco Colonna was born in Parma, Italy, received his medical degree at Parma University and completed his postdoctoral training at Harvard Medical School (Cambridge, Massachusetts, USA). He became a scientific member of the Basel Institute for Immunology in Basel, Switzerland. Since 2001 he has been a Professor of Pathology & Immunology at Washington University School of Medicine in St. Louis, MO. Dr. Colonna’s research focuses on immunoreceptors. In this field his accomplishments encompass identification and characterization of the Killer cell Ig-like receptors and HLA-C polymorphisms as their inhibitory ligands, as well as the discovery of the LILR and TREM inhibitory and activating receptor families. Through analysis of the cellular distribution of these receptors, he identified plasmacytoid dendritic cells as source of IFN-a/b in anti-viral responses and innate lymphoid cells that produce IL-22 in mucosae. His current areas of research include: 1) Innate lymphoid cells in mucosal immunity. 2) Plasmacytoid dendritic cells in host defense and autoimmunity. 3) Innate immunoreceptors in Alzheimer’s disease.
Prof Jolanda De Vries
Radboud UMC, Netherlands
Professor Jolanda de Vries is chair of the Department of Tumor Immunology at the Radboud Institute for Molecular Life Sciences. She was one of the pioneers to translate dendritic cell biology into potential clinical applications. The first clinical phase I/II studies in which patients were vaccinated with DCs loaded with tumour-specific peptides were initiated in 1997. She also developed a novel immuno-monitoring assay that is highly predictive for extended survival after vaccination with DCs. Her primary scientific interest continues along the line of DC-immunotherapy and in particular the migration and imaging of DC. For example, in-vivo imaging of ex-vivo labelled cells using MRI. New opportunities for other cell-types (e.g. subsets of DCs) are now being developed.
Dr Lélia Delamarre
Lélia Delamarre is a Senior Scientist in the Cancer Immunology Department at Genentech. The focus of her group is to understand how the modulation of dendritic cell and T cell functions can enhance tumor-specific T cell responses. Her lab also concentrates on the identification of the tumor antigens that drive T cell responses with the goal of further characterizing T cell responses in cancer patients and develop personalized immunotherapies against cancer. Lélia obtained a PhD in Virology from Pierre and Marie Curie University in France and then, completed a postdoctoral training at Yale University, where she studied the cell biology of antigen presentation in dendritic cells.
Prof Diana Dudziak
University of Erlangen, Germany
Prof Florent Ginhoux
Singapore Immunology Network (SIgN)
Agency for Science, Technology and Research (A*STAR), Singapore
Florent Ginhoux graduated in Biochemistry from the University Pierre et Marie CURIE (UPMC), Paris VI, obtained a Masters degree in Immunology from the Pasteur Institute in 2000 and his PhD in 2004 from UPMC, Paris VI. As a postdoctoral fellow, he joined the Laboratory of Miriam Merad in the Mount Sinai School of Medicine (MSSM), New York. In 2008, he became an Assistant Professor in the Department of Gene and Cell Medicine, MSSM and member of the Immunology Institute of MSSM. He joined the Singapore Immunology Network (SIgN), A*STAR in May 2009 as a Junior Principal Investigator. He is now a Senior Principal Investigator, an EMBO Young Investigator and a Web of Science Highly Cited Researcher since 2016. He is also an Adjunct Visiting Associate Professor in the Shanghai Immunology Institute, Jiao Tong University, in Shanghai, China since 2015. Both laboratories are focusing on the ontogeny and differentiation of macrophages and dendritic cells (DCs), in both humans and mice.
Prof Muzlifah Haniffa
Newcastle University, England
Muzlifah Haniffa is a Wellcome Trust Senior Research Fellow, Lister Institute Research Fellow and Consultant Dermatologist based in Newcastle University. She graduated from medical school in Cardiff and trained as a junior doctor in Cambridge. She received her dermatology specialist training in Newcastle. She was awarded an Action Medical Research Training Fellowship and a Wellcome Trust Clinical Intermediate Fellowship. Muzz was the recipient of the LEO Pharma/ESDR Silver Prize for Dermatology Research (2013), ACTERIA Prize in Immunology and Allergology (2018) and the Foulkes Foundation Medal (2019). Her research programme aims to understand the functional organisation of the developing and adult human immune system in health and disease.
Dr Sandrine Henri
CIML Immunology, France
Sandrine Henri did her PhD on immuno-parasitology at the Faculty of Medecine La Timone (Marseille, France) aiming to understand the mechanisms of susceptibility or resistance to Symmers fibrosis in sudanese populations infected by Schistosoma mansoni using immunological and genetic approaches. Then she was post-doctoral fellow at the Walter Eliza Hall Institute of Medical Research (WEHI, Melbourne, Australia) where she contributed to the characterization of dendritic cell subsets in skin and cutaneous lymph nodes and studied DC interaction with Leishmania major.
Prof Matthew Krummel
University of California, San Francisco, USA
Prof Christian Kurts
University of Bonn, Germany
Christian Kurts received his medical doctorate in 1991 from Göttingen University, Germany. He trained at Hannover and Aachen University clinic and was granted board certifications in internal medicine and nephrology. From 1995 until 1998, he worked with Profs. Miller, Carbone and Heath at the WEHI in Melbourne, where he defined antigen cross-presentation and studied its role in autoimmunity. In 2003, he was appointed tenured Professor at the University of Bonn, Germany, and in 2009 he became director of the Institute of Experimental Immunology in Bonn. He received a Heisenberg fellowship and the Gottfried-Wilhelm-Leibniz-Prize from the German Research Foundation and was elected in 2014 into the German National Academy of Sciences Leopoldina. He coordinates an international PhD and scientific exchange program between Bonn and Melbourne Universities. His research is focused at kidney dendritic cells, antigen presentation and on the mechanisms underlying various types of immune-mediated diseases.
A/Prof Mireille Lahoud
Monash Biomedicine Discovery Institute, Monash University, Melbourne, Australia
Assoc. Prof. Lahoud completed her PhD at Monash University, where she focussed on identification and functional analysis of novel DNA binding proteins. She then applied her molecular expertise to the molecular analysis of dendritic cell (DC) subsets at The Walter and Eliza Hall Institute. Assoc. Prof. Lahoud’s research focussed on the identification of DC-surface molecules that underpin DC function in mouse and human, and as DC targets for immune modulation. Her discoveries of DC receptors and their ligands have enhanced the understanding of DC subsets and their functions, and have revealed damage recognition pathways integral for immune responses. She has applied this knowledge of DC receptors and their functions for the development of a platform to modulate immune responses.
Assoc. Prof Lahoud now heads a research team at the Monash Biomedicine Discovery Institute, Monash University. Her research focusses on Dendritic Cell Receptors, their role in damage and pathogen recognition, and their application for vaccines and immune modulation.
Prof Bart Lambrecht
Ghent University, Belgium
Bart N. Lambrecht obtained an MD (1993) and PhD (1999) in Medicine at Ugent and specialized in
Pulmonary Medicine (2002) at Erasmus University Medical Center in Rotterdam, The Netherlands. He
is Professor of Pulmonary Medicine at ErasmusMC and at UGent, Belgium, and since 2012 the director of the VIB Inflammation Research Center, hosting 250 scientists . He is an ERC grant awardee and serves on the editorial board of Mucosal Immunology, Trends in Immunology and Journal of Experimental Medicine. He has (co)authored 330 papers in the field of asthma and allergy.
The thematic area of his group is centered around unraveling the role of antigen presenting dendritic cells (DC) and epithelial cells in the lungs in asthma and viral infection. His theories on the mechanisms of allergic sensitization are now the basis of many research efforts accross the globe, and offer prospects for the design of new preventive and therapeutic avenues for asthma. Still active as a clinician, Lambrecht is the example of a physician-scientist that can push the boundaries of basic science on asthma.
Prof Yuting Ma
Suzhou Institute of Systems Medicine, China
Yuting MA focuses on dissecting how cellular and mental stress responses modulate immune-related disorders, especially cancer. With the approaches of systems medicine, she is exploring: 1) cytotoxic agent-induced alternations in tumor and immune cells at the levels of gene transcription, post-transcriptional modification and metabolism, which affect tumor immunogenicity and anti-tumor immunity; 2) mental stress-related changes in neuroendocrine mediators and metabolites from host cells and microbiota, which can be sensed by immune cells to regulate the pathological outcome. Her publications in the field of tumor immunology reached >3900 citations in total. Yuting received her PhD degree in Immunology from Université Paris sud 11, followed by post-doc trainings in Institut Gustave Roussy (INSERM U848) and Université Paris Descartes (Centre de Recherche des Cordeliers), France. She is now a professor and a lab director in Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences. She received Chinese Young Women Scientists Awards in 2019.
Prof Kenneth Murphy
Washington University School of Medicine in St.Louis, Missouri
Dr. Ken Murphy obtained his MD and PhD from the Johns Hopkins University School of Medicine. In 1984, he began a residency in Pathology at Washington University School of Medicine in St. Louis. After this, he did postdoctoral work in molecular immunology with Dr. Dennis Loh, where he generated the DO11.10 TCR transgenic mouse used in studies of self-tolerance, and later in studies of Th1/Th2 development. In 1990, he joined the Pathology and Immunology Department at Washington University, where he is now full professor and an investigator of the Howard Hughes Medical Institute. His work has focused on important cell fate and lineage decisions during the development of the immune system and during immune responses to pathogens, particularly at the transcriptional level. His lab was the first to demonstrate that the innate immune system, through interactions with pathogens, controls the quality of the adaptive immune response, such as induction of Th1 development through macrophage- and dendritic cell-derived cytokines. Current work continues to focus on important fate decisions, such as the development of specialized subsets of dendritic cells involved in the activation of T cell responses to viral pathogens.
Prof Michel Nussenzweig
The Rockefeller University, USA
Dr. Nussenzweig was born in Sao Paulo Brazil on February 10th 1955. He received a B.S. summa cum laude from New York University in 1976, a Ph.D. degree from the Rockefeller University in 1981 and an M.D. degree from New York University Medical School in 1982. During his PhD with Ralph Steinman he discovered that dendritic cells are antigen presenting cells. After completing a medical internship, and residency, and infectious fellowship at the Massachusetts General Hospital he joined Dr. Philip Leder in the department of genetics at Harvard Medical School for postdoctoral training. He returned to Rockefeller University in 1990 as an assistant professor and Howard Hughes Investigator to head an independent laboratory. He was promoted to professor in 1996 and holds the Zanvil A. Cohn and Ralph M. Steinman Chair of Immunology. He is a member of the American Academy of Arts and Sciences, the US National Academy of Medicine and the US National Academy of Sciences.
Prof Stephen Nutt
Walter & Eliza Hall Institute for Medical Research, Melbourne, Australia
Stephen Nutt is a laboratory head at the Walter and Eliza Hall Institute of Medical Research and a Professor at the University of Melbourne. His research goal is to decipher the regulatory logic used by immune cells in making cell fate decisions and particularly how a select group of transcription factors act as the master regulators to program the immune response. A particular interest is to understand the transcriptional program that enables lymphocytes and dendritic cells to diversify into the many well-known functional subsets essential for protective immunity. He completed his PhD research at the Research Institute of Molecular Pathology, Vienna Austria, and after post-doctoral studies at the University of Cambridge returned to Australia to establish his research program focussing on lymphocyte differentiation. In 2016, he was elected as a Fellow of the Australian Academy of Science and is a NHMRC Senior Principal Research Fellow.
A/Prof Simon Phipps
QIMR Berghofer Medical Research Institute, Brisbane, Australia
Prof Boris Reizis
NYU Langone Health, USA
Boris did his Ph.D. thesis research in immunology with Irun R. Cohen at the Weizmann Institute, and trained as a postdoc with Philip Leder at Harvard Medical School. In 2003 he started his lab at Columbia University, where he became a professor in 2014. In 2015 he joined New York University School of Medicine (NYUSoM) as a professor in the departments of Pathology and Medicine. Boris is the director of NYUSoM Immunology and Inflammation Training program and the co-Director of the Colton Center for Autoimmunity. The Reizis lab has been broadly interested in hematopoiesis, differentiation and function of dendritic cells, and mechanisms of autoimmunity.
Dr Elodie Segura
Institute Curie, France
Elodie Segura received a Ph.D. in Immunology in 2006 for her work on dendritic cell-derived exosomes, carried out at the Institut Curie in Paris (France) under the supervision of Clotilde Théry. Elodie Segura was then a postdoctoral fellow in José Villadangos’ laboratory at the Walter and Eliza Hall Institute in Melbourne (Australia), working on the mechanisms of cross-presentation in murine dendritic cells. In 2010, she returned to Institut Curie in Paris (France) to undertake the analysis of human dendritic cell subsets in the laboratory of Sebastian Amigorena. Since 2013, she is a Principal Investigator within the “Immunity and Cancer” department at Institut Curie. Her work focuses on the biology of human antigen-presenting cells in health and disease. Elodie Segura is the current president of the French Dendritic Cell Society, and an Associate Editor at Frontiers in Immunology (section Antigen Presenting Cell Biology).
Prof Roxane Tussiwand
National Institutes of Health, USA
Roxane Tussiwand graduated in 2002 with a degree in biology from the University of Milan, where she worked on the prenatal origin of childhood leukemia. In 2006 she obtained an international PhD in molecular medicine sponsored by the Italian government at the Institute for Research in Biomedicine in Bellinzona, Switzerland, working on dendritic cell development. From 2006 to 2010 she worked on early hematopoietic development as postdoctoral fellow in the laboratory of A. Rolink at the University of Basel. In 2010 she joined the group of Ken Murphy, Washington University in St. Louis, USA, working on the transcriptional regulation of dendritic cell development. In October 2014 she was appointed as Swiss National Science Foundation Professor at the University of Basel. In February 2019 she was recruited at the NIDCR/NIH through the Stadtman Tenure-Track Investigator program. In 2016 she received the G.Thorbecke Award from the Society for leukocyte biology. Her research focuses on the transcriptional regulation of hematopoietic cells commitment and on dendritic cell biology.
Dr Linda Wakim
Doherty Institute, Melbourne